{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-079036","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2022-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.393335+00:00","generated_at":"2026-06-26T21:38:56.170322+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Forte Biosciences appoints Barbara K. Finck, M.D. to Board of Directors","bullets":["Appointment effective March 16, 2022; Dr. Finck will serve as a Class I director until 2024 annual meeting.","Annual cash retainer of $40,000, paid quarterly in arrears on a pro-rata basis.","Granted option for 50,000 shares of common stock vesting monthly over three years.","Dr. Finck currently acting Chief Medical Officer at Coherus BioSciences; prior CMO at NKT Therapeutics and Osprey Pharmaceuticals.","No arrangement with any other person for election; no family relationships with directors or officers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-079036","json":"https://secwatch.observer/filing/0001193125-22-079036.json","markdown":"https://secwatch.observer/filing/0001193125-22-079036.md","text":"https://secwatch.observer/filing/0001193125-22-079036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312522079036/0001193125-22-079036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312522079036/d322296d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:38:56.170322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9eb9934f75","claim":"Barbara K. Finck, M.D. was appointed as Director at Forte Biosciences, Inc..","evidence_excerpt":"appointed Barbara K. Finck, M.D. to the Board, effective March 16, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312522079036/0001193125-22-079036-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}